Physician profile
Kiersten Striebe
NPI 1891223103
$5,974.59
in general payments reported to CMS, 2019-2025
23 companies · $1,414 in 2025
The $1,414 reported for 2025 was more than what 88% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $496 · 2022: $1,517 · 2023: $1,496 · 2024: $1,052 · 2025: $1,414.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,824 · Education: $138.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,823.54 |
| Education | $137.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $945.66 | 2021-2025 | |
| Pfizer INC. | $795.41 | 2021-2025 | |
| Leo Pharma INC. | $548.67 | 2021-2025 | Adbry, Anzupgo, Spevigo |
| Sun Pharmaceutical Industries INC. | $475.00 | 2021-2025 | Ilumya, Absorica Ld, Winlevi |
| Incyte Corporation | $468.23 | 2022-2025 | Opzelura |
| Janssen Biotech, INC. | $466.13 | 2022-2025 | Tremfya |
| Lilly USA, LLC | $388.45 | 2022-2025 | Ebglyss, Taltz, Olumiant |
| Novartis Pharmaceuticals Corporation | $341.76 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $300.71 | 2021-2025 | Dupixent, Libtayo |
| E.R. Squibb & Sons, L.L.C. | $257.02 | 2022-2023 | Sotyktu |
| Genzyme Corporation | $248.46 | 2021-2025 | |
| Ucb, INC. | $190.99 | 2021-2025 | Bimzelx |
| Galderma Laboratories, L.P. | $144.36 | 2021-2025 | Nemluvio, Aklief |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $63.32 | 2021-2023 | Jublia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $59.53 | 2024-2025 | Spevigo |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $57.41 | 2025 | Otezla, Otezla |
| Dermavant Sciences, INC. | $45.44 | 2024 | Vtama |
| Organon LLC | $42.02 | 2025 | |
| Botanix Sb INC | $40.08 | 2025 | Sofdra |
| Mayne Pharma Commercial LLC | $37.49 | 2023 | |
| Verrica Pharmaceuticals INC. | $23.93 | 2023 | Ycanth |
| Arcutis Biotherapeutics, INC. | $19.23 | 2025 | Zoryve |
| Paratek Pharmaceuticals, INC. | $15.29 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kiersten Striebe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.